The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents

Sonia A Tucci, Emma J Boyland, Jason CG HalfordKissileff Laboratory for the Study of Human Ingestive Behaviour, School of Psychology, University of Liverpool, Liverpool, UKAbstract: Obesity is a global epidemic associated with significant morbidity and mortality in adults and ill health in children....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sonia A Tucci, Emma J Boyland, Jason CG Halford
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/a85fa1468fc84f3ca6822abd45ea5ece
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a85fa1468fc84f3ca6822abd45ea5ece
record_format	dspace
spelling	oai:doaj.org-article:a85fa1468fc84f3ca6822abd45ea5ece2021-12-02T01:46:00ZThe role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents1178-7007https://doaj.org/article/a85fa1468fc84f3ca6822abd45ea5ece2010-05-01T00:00:00Zhttp://www.dovepress.com/the-role-of-lipid-and-carbohydrate-digestive-enzyme-inhibitors-in-the--a4385https://doaj.org/toc/1178-7007Sonia A Tucci, Emma J Boyland, Jason CG HalfordKissileff Laboratory for the Study of Human Ingestive Behaviour, School of Psychology, University of Liverpool, Liverpool, UKAbstract: Obesity is a global epidemic associated with significant morbidity and mortality in adults and ill health in children. A proven successful approach in weight management has been the disruption of nutrient digestion, with orlistat having been used to treat obesity for the last 10 years. Although orlistat-induced weight loss remains modest, it produces meaningful reductions in risk factors for obesity-related conditions such as diabetes and cardiovascular disease. Moreover, this lipase inhibitor is free of the serious side effects that have dogged appetite-suppressing drugs. This success had driven investigation into new generation nutraceuticals, supplements and pharmaceutical agents that inhibit the breakdown of complex carbohydrates and fats within the gut. This review focuses on agents purported to inhibit intestinal enzymes responsible for macronutrient digestion. Except for some synthetic products, the majority of agents reviewed are either botanical extracts or bacterial products. Currently, carbohydrate digestion inhibitors are under development to improve glycemic control and these may also induce some weight loss. However, colonic fermentation induced side effects, such as excess gas production, remain an issue for these compounds. The &alpha;-glucosidase inhibitor acarbose, and the &alpha;-amylase inhibitor phaseolamine, have been used in humans with some promising results relating to weight loss. Nonetheless, few of these agents have made it into clinical studies and without any clinical proof of concept or proven efficacy it is unlikely any will enter the market soon.Keywords: lipase, amylase, saccharidases, overweight, orlistat, Alli&reg;, digestion, body weight Sonia A TucciEmma J BoylandJason CG HalfordDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2010, Iss default, Pp 125-143 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Sonia A Tucci Emma J Boyland Jason CG Halford The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
description	Sonia A Tucci, Emma J Boyland, Jason CG HalfordKissileff Laboratory for the Study of Human Ingestive Behaviour, School of Psychology, University of Liverpool, Liverpool, UKAbstract: Obesity is a global epidemic associated with significant morbidity and mortality in adults and ill health in children. A proven successful approach in weight management has been the disruption of nutrient digestion, with orlistat having been used to treat obesity for the last 10 years. Although orlistat-induced weight loss remains modest, it produces meaningful reductions in risk factors for obesity-related conditions such as diabetes and cardiovascular disease. Moreover, this lipase inhibitor is free of the serious side effects that have dogged appetite-suppressing drugs. This success had driven investigation into new generation nutraceuticals, supplements and pharmaceutical agents that inhibit the breakdown of complex carbohydrates and fats within the gut. This review focuses on agents purported to inhibit intestinal enzymes responsible for macronutrient digestion. Except for some synthetic products, the majority of agents reviewed are either botanical extracts or bacterial products. Currently, carbohydrate digestion inhibitors are under development to improve glycemic control and these may also induce some weight loss. However, colonic fermentation induced side effects, such as excess gas production, remain an issue for these compounds. The &alpha;-glucosidase inhibitor acarbose, and the &alpha;-amylase inhibitor phaseolamine, have been used in humans with some promising results relating to weight loss. Nonetheless, few of these agents have made it into clinical studies and without any clinical proof of concept or proven efficacy it is unlikely any will enter the market soon.Keywords: lipase, amylase, saccharidases, overweight, orlistat, Alli&reg;, digestion, body weight
format	article
author	Sonia A Tucci Emma J Boyland Jason CG Halford
author_facet	Sonia A Tucci Emma J Boyland Jason CG Halford
author_sort	Sonia A Tucci
title	The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
title_short	The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
title_full	The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
title_fullStr	The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
title_full_unstemmed	The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
title_sort	role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/a85fa1468fc84f3ca6822abd45ea5ece
work_keys_str_mv	AT soniaatucci theroleoflipidandcarbohydratedigestiveenzymeinhibitorsinthemanagementofobesityareviewofcurrentandemergingtherapeuticagents AT emmajboyland theroleoflipidandcarbohydratedigestiveenzymeinhibitorsinthemanagementofobesityareviewofcurrentandemergingtherapeuticagents AT jasoncghalford theroleoflipidandcarbohydratedigestiveenzymeinhibitorsinthemanagementofobesityareviewofcurrentandemergingtherapeuticagents AT soniaatucci roleoflipidandcarbohydratedigestiveenzymeinhibitorsinthemanagementofobesityareviewofcurrentandemergingtherapeuticagents AT emmajboyland roleoflipidandcarbohydratedigestiveenzymeinhibitorsinthemanagementofobesityareviewofcurrentandemergingtherapeuticagents AT jasoncghalford roleoflipidandcarbohydratedigestiveenzymeinhibitorsinthemanagementofobesityareviewofcurrentandemergingtherapeuticagents
_version_	1718402914144223232

The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents

Ejemplares similares